Test-Retest Evaluation of [18F]F-AraG in Lung Tumors (TREAT)
Key facts
- Where
- Amsterdam, HollandiaSee the site
- Phase
- 2/3. fázis
Where in Hollandia
- Amsterdam UMC StichtingAmsterdam, HollandiaToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Amsterdam UMC Stichting
- Trial code
- EU 2025-522404-24-01
- Record updated
- 2026. január 27.
- Original description
To measure the variability in tumor and organ uptake between two, closely obtained, [18F]F-AraG PET scans.Read full original descriptionShow less
To measure the variability in tumor and organ uptake between two, closely obtained, [18F]F-AraG PET scans.
Inclusion: Histologically confirmed lung cancer 2. At least 1 lesion with size of ≥2cm 3. Willing and able to provide written informed consent for the trial 4. Above 18 years of age on day of signing informed consent 5. Have measurable disease based on RECIST 1.1.
Exclusion: Patients on active immunomodulatory treatment 2. Patients with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of day 0. Inhaled or topical steroids, and adrenal replacement steroid >10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease. 3. Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. 4. Patient is pregnant or breastfeeding or expecting to conceive within the projected duration of the trial.